Abstract:Expression of bone proteins resulting from transdifferentiation of vascular smooth muscle cells into osteoblasts suggests that vascular calcifications are a bioactive process. Regulating molecules such as osteoprotegerin (OPG) and receptor activator of NF-kappaB ligand (RANKL) could play a key role in bone-vascular calcification imbalance. This study investigated the contribution of these proteins as well as mineral metabolism disorders in hemodialysis (HD) patient outcome. A total of 185 HD patients were followed up prospectively for 2 yr. In addition to clinical characteristics, mineral metabolism markers as well as OPG and soluble RANKL (sRANKL) were measured at baseline. After 2 yr, survival rates were described with Kaplan-Meier and compared with Cox regression analyses; 50 patients died (27 from cardiovascular diseases). Calcium, phosphate, and calcium x phosphate product were not associated with mortality. Both hyperparathyroidism (parathyroid hormone > or =300 pg/ml) and hypoparathyroidism (parathyroid hormone <150 pg/ml) were poorly associated with all-cause and cardiovascular mortality. By contrast, elevated OPG levels predicted all-cause (relative risk [RR] 2.67; 95% confidence interval [CI] 1.32 to 5.41; P = 0.006) and cardiovascular mortality (RR 3.15; 95% CI 1.14 to 8.69; P = 0.03). Low levels of sRANKL were associated with a protective effect for all-cause mortality (RR 0.45; 95% CI 0.21 to 0.94; P = 0.03). The association of OPG with all-cause mortality was stronger in patients with C-reactive protein > or =12.52 mg/L. In this condition, both highest (RR 5.68; 95% CI 1.48 to 22.73; P = 0.01) and lowest tertiles (RR 5.37; 95% CI 147 to 1968; P = 0.01) significantly predicted poor outcome. These results show that regulating-bone molecules, especially OPG, are strong predictors of mortality in HD patients, suggesting that OPG is a vascular risk factor, in particular in patients who have high C-reactive protein levels. OPG determination therefore should be added to the biologic follow-up of these patients.

Osteoprotegerin and Vascular Calcification

The Role of Osteoprotegerin in Vascular Calcification and Bone Metabolism: The Basis for Developing New Therapeutics

Research progress of osteoprotegerin in cardiovascular disease

The effects of osteoprotegerin on the activity of osteoclasts

Osteoprotegerin Influences The Bone Resorption Activity Of Osteoclasts

Effect of Simvastatin on Osteoprotegerin Expression in Bone Callus of Ovariectimized Rats

Bone marrow- or vessel wall-derived osteoprotegerin is sufficient to reduce atherosclerotic lesion size and vascular calcification

Effect of osteoprotegerin on osteoclasts

The Role of Osteoprotegerin and Its Ligands in Vascular Function

PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways.

High-Bone-Turnover Osteoporosis and Aortic Calcification in Opg Knockout Mice

Increased expression of osteoprotegerin in vascular smooth muscle cells from spontaneously hypertensive rats

Inhibitory Effects of Osteoprotegerin on Osteoclast Formation and Function under Serum-Free Conditions

Plasma Osteoprotegerin Is Associated with Mortality in Hemodialysis Patients

Osteopontin Regulates Macrophage Activation and Osteoclast Formation in Hypertensive Patients with Vascular Calcification

Effects of Parathyroid Hormone on Osteoprotegerin Expression and Osteoprotegerin Ligand and Their Related Cytokines in Human Osteoblasts

Osteoprotegerin Promotes Cementoblastic Activity of Murine Cementoblast Cell Line in Vitro.

Omentin-1 Attenuates Arterial Calcification and Bone Loss in Osteoprotegerin-Deficient Mice by Inhibition of RANKL Expression.

Mechanistic study of the proangiogenic effect of osteoprotegerin

9A.03: OSTEOPONTIN AND OSTEOPROTEGERIN ACTIVATE MONOCYTES INTO ANTI-INFLAMMATORY PROPERTIES IN THE PATIENTS WITH HYPERTENSION-RELATED VASCULAR CALCIFICATION.

Effect of Four Different Anti-Osteoporosis Agents on the Expression of Matrix Gla Protein in Primary Osteoblasts of SD Rat